Ironwood Pharmaceuticals (IRWD) : Analyst Rating Update

Ironwood Pharmaceuticals (IRWD) : The consensus on Ironwood Pharmaceuticals (IRWD) based on 8 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Ironwood Pharmaceuticals (IRWD) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $16 and the lowest price target forecast is $10. The average forecast of all the analysts is $12.57 and the expected standard deviation is $2.7.

Ironwood Pharmaceuticals (NASDAQ:IRWD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $13.01 and $12.97 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $13.19. The buying momentum continued till the end and the stock did not give up its gains. It closed at $13.15, notching a gain of 0.69% for the day. The total traded volume was 886,478 . The stock had closed at $13.06 on the previous day.

Also, Cowen & Company upgrades its view on Ironwood Pharmaceuticals (NASDAQ:IRWD) according to the research report released by the firm to its investors. The shares have now been rated Outperform by the stock experts at the ratings house. Earlier, the shares had a rating of Market Perform. The rating by the firm was issued on April 6, 2016. The company shares have rallied 10.12% from its 1 Year high price. On Jun 9, 2016, the shares registered one year high at $13.27 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $12.53 and the 200 Day Moving Average price is recorded at $10.87.

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.